Specifications
- Purity
- ≥99% (HPLC)
- Appearance
- White to off-white solid
- Identity
- 1H-NMR
Properties
- Solvents
- DMSO or DMF (both 20 mg/ml), ethanol (1mg/ml) or water (<1mg/ml)
Category: API's & Intermediates
MK-4827 is an orally bioavailable inhibitor of poly(ADP-ribose) polymerase 1 (PARP1) and PARP2 (IC50s=3.8 and 2.1nM, respectively). It inhibits the proliferation of cancer cells carrying the breast cancer mutations BRCA1 and BRCA2 in vitro and has efficacy alone against a xenograft of BRCA1-deficient cancer in mice. MK-4827 sensitizes human lung and breast cancer xenografts to radiation in mice.3 Formulations containing MK-4827 are effective against ovarian cancer.
Synonyms | Niraparib tosylate, (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide 4 methylbenzenesulfonate |
---|---|
Purity | ≥99% (HPLC) |
Appearance | White to off-white solid |
CAS-Number | 1038915-73-9 |
Molecular Formula | C19H20N4O.C7H8O3S |
Molecular Weight | 492.6 |
Identity | 1H-NMR |
Solvents | DMSO or DMF (both 20 mg/ml), ethanol (1mg/ml) or water (<1mg/ml) |
Smiles | NC(C1=CC=CC2=CN(C3=CC=C([C@H]4C[NH2+]CCC4)C=C3)N=C21)=O.CC5=CC=C(S(=O)([O-])=O)C=C5 |
InChi Key | LCPFHXWLJMNKNC-PFEQFJNWSA-N |
Shipping | AMBIENT |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Handling Advice | Protect from light and moisture. |
Use / Stability | Stable for at least 2 years after receipt when stored at -20°C. |
Transportation | Not dangerous goods |
References | (1) P. Jones, et al., J. Med. Chem. 52, 7170 (2009), (2) Y. Yuan, et al., J. Hematol. Oncol. 4, 1 (2011), (3) L. Wang, et al., Invest. New Drugs 30, 2113 (2012), (4) M.R. Mirza, et al., N. Engl. J. Med. 375, 2154 (2016), (5) K.N. Moore, et al., Gynecol. Oncol. 149, 214 (2018) (Review) |
Quantity | 10 mg, 50 mg, Bulk |